CG
NVO

Caprock Group’s Novo Nordisk NVO Stock Holding History

Caprock Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59M Sell
41,837
-2,260
-5% -$107K 0.04% 412
2025
Q4 		$2.24M Sell
44,097
-5,208
-11% -$266K 0.05% 343
2025
Q3 		$2.78M Buy
+49,305
New +$2.89M 0.07% 261
2025
Q1 		$4.26M Sell
60,404
-1,861
-3% -$154K 0.13% 132
2024
Q4 		$5.36M Buy
62,265
+1,013
+2% +$110K 0.18% 91
2024
Q3 		$7.29M Buy
+61,252
New +$8.17M 0.27% 64
2024
Q2 		– Sell
-28,215
Closed -$3.65M – 895
2024
Q1 		$3.65M Sell
28,215
-3,402
-11% -$405K 0.21% 68
2023
Q4 		$3.27M Sell
31,617
-2,762
-8% -$273K 0.21% 71
2023
Q3 		$3.13M Buy
34,379
+947
+3% +$83.4K 0.24% 63
2023
Q2 		$2.71M Buy
33,432
+898
+3% +$73.4K 0.2% 76
2023
Q1 		$2.61M Sell
32,534
-2,576
-7% -$183K 0.2% 74
2022
Q4 		$2.38M Buy
35,110
+520
+2% +$30.5K 0.22% 72
2022
Q3 		$1.72M Buy
34,590
+1,956
+6% +$105K 0.17% 86
2022
Q2 		$1.82M Sell
32,634
-1,046
-3% -$58K 0.18% 82
2022
Q1 		$1.89M Sell
33,680
-808
-2% -$41.5K 0.18% 95
2021
Q4 		$1.93M Sell
34,488
-856
-2% -$46.4K 0.16% 94
2021
Q3 		$1.7M Sell
35,344
-9,804
-22% -$474K 0.15% 96
2021
Q2 		$1.89M Sell
45,148
-640
-1% -$24.8K 0.17% 92
2021
Q1 		$1.56M Buy
45,788
+1,596
+4% +$56.8K 0.17% 96
2020
Q4 		$1.54M Buy
44,192
+134
+0.3% +$4.63K 0.18% 97
2020
Q3 		$1.53M Buy
44,058
+326
+0.7% +$10.9K 0.21% 87
2020
Q2 		$1.43M Sell
43,732
-7,148
-14% -$228K 0.22% 83
2020
Q1 		$1.55M Buy
50,880
+2,656
+6% +$79.1K 0.29% 67
2019
Q4 		$1.4M Sell
48,224
-150
-0.3% -$4.15K 0.25% 80
2019
Q3 		$1.25M Sell
48,374
-1,376
-3% -$34.8K 0.24% 79
2019
Q2 		$1.27M Buy
49,750
+142
+0.3% +$3.51K 0.25% 78
2019
Q1 		$1.32M Buy
49,608
+206
+0.4% +$5.06K 0.26% 77
2018
Q4 		$1.14M Buy
49,402
+2,218
+5% +$49.3K 0.26% 77
2018
Q3 		$1.11M Hold
47,184
– – 0.23% 87
2018
Q2 		$1.09M Buy
47,184
+950
+2% +$22.6K 0.23% 83
2018
Q1 		$1.16M Buy
46,234
+368
+0.8% +$9.66K 0.25% 74
2017
Q4 		$1.26M Buy
45,866
+74
+0.2% +$1.88K 0.25% 78
2017
Q3 		$1.1M Sell
45,792
-560
-1% -$12.7K 0.23% 80
2017
Q2 		$994K Buy
46,352
+2,230
+5% +$45K 0.22% 89
2017
Q1 		$756K Sell
44,122
-2,058
-4% -$35.8K 0.18% 112
2016
Q4 		$828K Sell
46,180
-5,302
-10% -$96.1K 0.21% 100
2016
Q3 		$1.07M Buy
51,482
+15,476
+43% +$384K 0.24% 98
2016
Q2 		$968K Sell
36,006
-4,568
-11% -$125K 0.24% 104
2016
Q1 		$1.1M Buy
+40,574
New +$1.09M 0.26% 89

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Caprock Group's NVO Position: Q1 2026 in Review

Caprock Group reduced its Novo Nordisk (NVO) stake by 5.1% in Q1 2026, selling an estimated $107K and leaving 41,837 shares worth $1.59M. The position accounts for 0.04% of the portfolio, ranked #412.

Caprock Group first reported a position in NVO in Q1 2016 and has held it in 39 quarters since. The position peaked at $7.29M in Q3 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Caprock Group held 41,837 shares of Novo Nordisk worth $1.59M as of Q1 2026.
  • Caprock Group sold 2,260 Novo Nordisk shares in Q1 2026, an estimated $107K.
  • Novo Nordisk made up 0.04% of Caprock Group's portfolio in Q1 2026, its #412 holding.
  • Caprock Group first reported a position in Novo Nordisk in Q1 2016 and has held it in 39 quarters since.
  • Caprock Group's Novo Nordisk position peaked at $7.29M in Q3 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.